Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP followed by alemtuzumab as salvage therapy in purine analogue-refractory/relapsed CLL
2007-003097-26Phase 2Active
- Sponsor
- Francesc Bosch Albareda
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Francesc Bosch Albareda. Primary endpoints: Overall response rate after R-CHOP followed by alemtuzumab and Molecular complete response rate after R-CHOP. Started Nov 2007; status: active.
02
Drugs
rituximabalemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2007-003097-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003097-26.